Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells

Molecular Therapy

Volumn 18, Issue 7, 2010, Pages 1346-1356

  Sivalingam, Jaichandran ^a,b   Krishnan, Shruti ^a   Ng, Wai Har ^a   Lee, Sze Sing ^a   Phan, Toan Thang ^b,c   Kon, Oi Lian ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c CellResearch Corp Pte Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; INTEGRASE; TRANSCRIPTOME;

ARTICLE; BACTERIOPHAGE; BINDING SITE; BIOSAFETY; CARCINOGENICITY; CELL CULTURE; CONTROLLED STUDY; EMBRYO CELL; EPITHELIUM CELL; EXON; GENE CONSTRUCT; GENE DOSAGE; GENE EXPRESSION; GENE INTERACTION; GENE LOCATION; GENE MAPPING; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSFECTION; GENOTOXICITY; HEMOPHILIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INTRON; KARYOTYPE; OUTER MEMBRANE; PHENOTYPE; PROTEIN SECRETION; TRANSCRIPTOMICS; TRANSGENE; UMBILICAL CORD; UMBILICAL CORD LINING CELL; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPORATION; EPITHELIAL CELLS; FACTOR VIII; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MICE; MICE, SCID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TRANSGENES; UMBILICAL CORD;

MUS;

EID: 77954244026     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.61     Document Type: Article

References (50)

1. Weiss, ML and Troyer, DL (2006). Stem cells in the umbilical cord. Stem Cell Rev 2: 155-162.
2. Harris, DT and Rogers, I (2007). Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine. Curr Stem Cell Res Ther 2: 301-309.
3. Miki, T and Strom, SC (2006). Amnion-derived pluripotent/multipotent stem cells. Stem Cell Rev 2: 133-142.
4. Ruetze, M, Gallinat, S, Lim, IJ, Chow, E, Phan, TT, Staeb, F et al. (2008). Common features of umbilical cord epithelial cells and epidermal keratinocytes. J Dermatol Sci 50: 227-231.
5. Phan, TT and Lim, IJ. Isolation of stem/progenitor cells from amniotic membrane of umbilical cord. UK Patent No. GB 2432166, granted 2 January 2008.
6. Matikainen, T and Laine, J (2005). Placenta-an alternative source of stem cells. Toxicol Appl Pharmacol 207(2 suppl.): 544-549.
7. Kurtzberg, J (2009). Update on umbilical cord blood transplantation. Curr Opin Pediatr 21: 22-29.
8. Secco, M, Zucconi, E, Vieira, NM, Fogaça, LL, Cerqueira, A, Carvalho, MD et al. (2008). Multipotent stem cells from umbilical cord: cord is richer than blood! Stem Cells 26: 146-150.
9. Kermani, AJ, Fathi, F and Mowla, SJ (2008). Characterization and genetic manipulation of human umbilical cord vein mesenchymal stem cells: potential application in cell-based gene therapy. Rejuvenation Res 11: 379-386.
10. Can, A and Karahuseyinoglu, S (2007). Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 25: 2886-2895.
11. Pfeifer, A and Verma, IM (2001). Gene therapy: promises and problems. Annu Rev Genomics Hum Genet 2: 177-211.
12. Hacein-Bey-Abina, S, Garrigue, A, Wang, G P, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
13. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
14. Kohn, DB (2008). Gene therapy for childhood immunological diseases. Bone Marrow Transplant 41: 199-205.
15. Chalberg, TW, Portlock, JL, Olivares, EC, Thyagarajan, B, Kirby, PJ, Hillman, RT et al. (2006). Integration specifcity of phage phiC31 integrase in the human genome. J Mol Biol 357: 28-48.
16. Held, PK, Olivares, EC, Aguilar, CP, Finegold, M, Calos, MP and Grompe, M (2005). In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 11: 399-408.
17. Bertoni, C, Jarrahian, S, Wheeler, TM, Li, Y, Olivares, EC, Calos, MP et al. (2006). Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci USA 103: 419-424.
18. Calos, MP (2006). The phiC31 integrase system for gene therapy. Curr Gene Ther 6: 633-645.
19. Thyagarajan, B, Liu, Y, Shin, S, Lakshmipathy, U, Scheyhing, K, Xue, H et al. (2008). Creation of engineered human embryonic stem cell lines using phiC31 integrase. Stem Cells 26: 119-126.
20. Ehrhardt, A, Xu, H, Huang, Z, Engler, JA and Kay, MA (2005). A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol Ther 11: 695-706.
21. Liu, J, Jeppesen, I, Nielsen, K and Jensen, TG (2006). Phi c31 integrase induces chromosomal aberrations in primary human fbroblasts. Gene Ther 13: 1188-1190.
22. Liu, J, Skjørringe, T, Gjetting, T and Jensen, TG (2009). PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fbroblasts. BMC Biotechnol 9: 31.
23. Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
24. Recchia, A, Bonini, C, Magnani, Z, Urbinati, F, Sartori, D, Muraro, S et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103: 1457-1462.
25. Kallioniemi, A (2008). CGH microarrays and cancer. Curr Opin Biotechnol 19: 36-40.
26. Giardino, D, Corti, C, Ballarati, L, Colombo, D, Sala, E, Villa, N et al. (2009). De novo balanced chromosome rearrangements in prenatal diagnosis. Prenat Diagn 29: 257-265.
27. Warburton, D (1991). De novo balanced chromosome rearrangements and extra marker chromosomes identifed at prenatal diagnosis: clinical signifcance and distribution of breakpoints. Am J Hum Genet 49: 995-1013.
28. Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
29. Ortiz-Urda, S, Thyagarajan, B, Keene, DR, Lin, Q, Fang, M, Calos, MP et al. (2002). Stable nonviral genetic correction of inherited human skin disease. Nat Med 8: 1166-1170.
30. Sclimenti, CR, Thyagarajan, B and Calos, MP (2001). Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res 29: 5044-5051.
31. Keravala, A, Lee, S, Thyagarajan, B, Olivares, EC, Gabrovsky, VE, Woodard, LE et al. (2009). Mutational derivatives of PhiC31 integrase with increased effciency and specifcity. Mol Ther 17: 112-120.
32. Affymetrix, Inc. Design and performance of the genechip human genome U133 plus 2.0 and human genome U133A 2.0 arrays. Technical note. Accessed 15 September 2009.
33. Futreal, PA, Coin, L, Marshall, M, Down, T, Hubbard, T, Wooster, R et al. (2004). A census of human cancer genes. Nat Rev Cancer 4: 177-183.
34. Ehrhardt, A, Engler, JA, Xu, H, Cherry, AM and Kay, MA (2006). Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 17: 1077-1094.
35. Varella-Garcia, M, Chen, L, Powell, RL, Hirsch, FR, Kennedy, TC, Keith, R et al. (2007). Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer. Am J Respir Crit Care Med 176: 505-512.
36. Hahn, WC and Weinberg, RA (2002). Rules for making human tumor cells. N Engl J Med 347: 1593-1603.
37. Mitelman, F, Johansson, B and Mertens, F (2004). Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 36: 331-334.
38. Lowe, SW, Cepero, E and Evan, G (2004). Intrinsic tumour suppression. Nature 432: 307-315.
39. Mahale, AM, Khan, ZA, Igarashi, M, Nanjangud, GJ, Qiao, RF, Yao, S et al. (2008). Clonal selection in malignant transformation of human fbroblasts transduced with defned cellular oncogenes. Cancer Res 68: 1417-1426.
40. Dwarki, VJ, Belloni, P, Nijjar, T, Smith, J, Couto, L, Rabier, M et al. (1995). Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 92: 1023-1027.
41. Larcher, F, Dellambra, E, Rico, L, Bondanza, S, Murillas, R, Cattoglio, C et al. (2007). Long-term engraftment of single genetically modifed human epidermal holoclones enables safety pre-assessment of cutaneous gene therapy. Mol Ther 15: 1670-1676.
42. Parrish, EP, Steart, PV, Garrod, DR and Weller, RO (1987). Antidesmosomal monoclonal antibody in the diagnosis of intracranial tumours. J Pathol 153: 265-273.
43. Allen, J, Phan, TT, Hughes, MA, Cherry, GW and Wojnarowska, F (2003). The cellular origins of the linear IgA disease target antigens: an indirect immunofuorescence study using cultured human keratinocytes and fbroblasts. Br J Dermatol 148: 945-953.
44. Miao, HZ, Sirachainan, N, Palmer, L, Kucab, P, Cunningham, MA, Kaufman, RJ et al. (2004). Bioengineering of coagulation factor VIII for improved secretion. Blood 103: 3412-3419.
45. Swaroop, M, Moussalli, M, Pipe, SW and Kaufman, RJ (1997). Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem 272: 24121-24124.
46. Groth, AC, Olivares, EC, Thyagarajan, B and Calos, MP (2000). A phage integrase directs effcient site-specifc integration in human cells. Proc Natl Acad Sci USA 97: 5995-6000.
47. Wang, GP, Garrigue, A, Ciuff, A, Ronen, K, Leipzig, J, Berry, C et al. (2008). DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res 36: e49.
48. Knoll, JH, Lichter, P, Bakdounes, K and Eltoum, IE (2007). In situ hybridization and detection using nonisotopic probes. Curr Protoc Mol Biol Chapter 14: Unit 14.7.
49. Bi, L, Lawler, AM, Antonarakis, SE, High, KA, Gearhart, JD and Kazazian, HH Jr (1995). Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 10: 119-121.
50. Rawle, FE and Lillicrap, D (2004). Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost 30: 205-213.